Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.

Original languageEnglish
Pages (from-to)473-482
Number of pages10
JournalBreast Cancer
Volume24
Issue number3
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Estrogen Receptors
Breast Neoplasms
Recurrence
Survival
Drug Therapy
Adjuvant Chemotherapy

Keywords

  • Breast cancer
  • Endocrine therapy
  • Estrogen receptor-positive
  • Post-relapse survival
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. / Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.

In: Breast Cancer, Vol. 24, No. 3, 01.05.2017, p. 473-482.

Research output: Contribution to journalArticle

Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society 2017, 'Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer', Breast Cancer, vol. 24, no. 3, pp. 473-482. https://doi.org/10.1007/s12282-016-0730-3
Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. / Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. In: Breast Cancer. 2017 ; Vol. 24, No. 3. pp. 473-482.
@article{30fc4699c33b4b1e8ec2273b660711e4,
title = "Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer",
abstract = "Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.",
keywords = "Breast cancer, Endocrine therapy, Estrogen receptor-positive, Post-relapse survival, Prognosis",
author = "{Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society} and Akiko Ogiya and Kieko Yamazaki and Rie Horii and Tadahiko Shien and Yoshiya Horimoto and Norikazu Masuda and Touko Inao and Mitsuchika Hosoda and Naoko Ishida and Tomofumi Osako and Masato Takahashi and Yumi Endo and Yuichiro Miyoshi and Hiroyuki Yasojima and Nobumoto Tomioka and Hiroko Yamashita",
year = "2017",
month = "5",
day = "1",
doi = "10.1007/s12282-016-0730-3",
language = "English",
volume = "24",
pages = "473--482",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

AU - Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society

AU - Ogiya, Akiko

AU - Yamazaki, Kieko

AU - Horii, Rie

AU - Shien, Tadahiko

AU - Horimoto, Yoshiya

AU - Masuda, Norikazu

AU - Inao, Touko

AU - Hosoda, Mitsuchika

AU - Ishida, Naoko

AU - Osako, Tomofumi

AU - Takahashi, Masato

AU - Endo, Yumi

AU - Miyoshi, Yuichiro

AU - Yasojima, Hiroyuki

AU - Tomioka, Nobumoto

AU - Yamashita, Hiroko

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.

AB - Background: Few studies have been performed on post-relapse survival in patients with the early and late distant recurrence in estrogen receptor (ER)-positive, HER2-negative breast cancer. Methods: A total of 205 patients with the early distant recurrence and 134 patients with the late distant recurrence of ER-positive, HER2-negative breast cancer who had undergone breast surgery or neoadjuvant chemotherapy between January 2000 and December 2004 were registered from nine institutions. Prognostic factors for post-relapse survival in patients with the early and late recurrence were analyzed. Results: Post-relapse survival was significantly longer in patients with the late recurrence than in patients with the early recurrence. Predictive factors for post-relapse survival in patients with the early recurrence were lack of adjuvant chemotherapy, a long disease-free interval, and long durations of endocrine therapies and chemotherapies after relapse. In patients with the late recurrence, post-relapse survival was significantly improved for those individuals with one metastatic organ at relapse and individuals who were treated with the first-line and subsequent endocrine therapies for prolonged periods. Moreover, ER expression in primary breast tumors of late recurrence patients was significantly higher with a duration of the first-line endocrine therapy >6 months than in those with a duration ≤6 months. Conclusion: Predictors for prognosis after relapse differed between patients with the early and late distant recurrence. Endocrine responsiveness after relapse is a key factor for improved post-relapse survival, and it is thus important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.

KW - Breast cancer

KW - Endocrine therapy

KW - Estrogen receptor-positive

KW - Post-relapse survival

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84988443341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988443341&partnerID=8YFLogxK

U2 - 10.1007/s12282-016-0730-3

DO - 10.1007/s12282-016-0730-3

M3 - Article

C2 - 27628678

AN - SCOPUS:84988443341

VL - 24

SP - 473

EP - 482

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 3

ER -